Aberrant DNA methylation of <i>PTPRG</i> as one possible mechanism of its under‐expression in CML patients in the State of Qatar
<h3>Background</h3><p dir="ltr">Several studies showed that aberrant DNA methylation is involved in leukemia and cancer pathogenesis. Protein tyrosine phosphatase receptor gamma (PTPRG) expression is a natural inhibitory mechanism that is downregulated in chronic myeloid...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , , , , , , |
| منشور في: |
2020
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513512404942848 |
|---|---|
| author | Mohamed A. Ismail (418629) |
| author2 | Muthanna Samara (11619435) Ali Al Sayab (4166521) Mohamed Alsharshani (14778928) Mohamed A. Yassin (8361183) Govindarajulu Varadharaj (14778931) Marzia Vezzalini (212801) Luisa Tomasello (702932) Maria Monne (4166524) Hisham Morsi (14152881) M. Walid Qoronfleh (14153088) Hatem Zayed (835448) Richard Cook (70389) Claudio Sorio (212799) Helmout Modjtahedi (532099) Nader I. Al‐Dewik (14778934) |
| author2_role | author author author author author author author author author author author author author author author |
| author_facet | Mohamed A. Ismail (418629) Muthanna Samara (11619435) Ali Al Sayab (4166521) Mohamed Alsharshani (14778928) Mohamed A. Yassin (8361183) Govindarajulu Varadharaj (14778931) Marzia Vezzalini (212801) Luisa Tomasello (702932) Maria Monne (4166524) Hisham Morsi (14152881) M. Walid Qoronfleh (14153088) Hatem Zayed (835448) Richard Cook (70389) Claudio Sorio (212799) Helmout Modjtahedi (532099) Nader I. Al‐Dewik (14778934) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohamed A. Ismail (418629) Muthanna Samara (11619435) Ali Al Sayab (4166521) Mohamed Alsharshani (14778928) Mohamed A. Yassin (8361183) Govindarajulu Varadharaj (14778931) Marzia Vezzalini (212801) Luisa Tomasello (702932) Maria Monne (4166524) Hisham Morsi (14152881) M. Walid Qoronfleh (14153088) Hatem Zayed (835448) Richard Cook (70389) Claudio Sorio (212799) Helmout Modjtahedi (532099) Nader I. Al‐Dewik (14778934) |
| dc.date.none.fl_str_mv | 2020-07-23T06:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1002/mgg3.1319 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Aberrant_DNA_methylation_of__i_PTPRG_i__as_one_possible_mechanism_of_its_under_expression_in_CML_patients_in_the_State_of_Qatar/22258273 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biological sciences Genetics Biomedical and clinical sciences Oncology and carcinogenesis aberrant DNA cancer CML epigenetics methylation PTPRG Qatar |
| dc.title.none.fl_str_mv | Aberrant DNA methylation of <i>PTPRG</i> as one possible mechanism of its under‐expression in CML patients in the State of Qatar |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background</h3><p dir="ltr">Several studies showed that aberrant DNA methylation is involved in leukemia and cancer pathogenesis. Protein tyrosine phosphatase receptor gamma (PTPRG) expression is a natural inhibitory mechanism that is downregulated in chronic myeloid leukemia (CML) disease. The mechanism behind its downregulation has not been fully elucidated yet.</p><h3>Aim</h3><p dir="ltr">This study aimed to investigate the CpG methylation status at the <i>PTPRG</i> locus in CML patients.</p><h3>Methods</h3><p dir="ltr">Peripheral blood samples from CML patients at time of diagnosis [no tyrosine kinase inhibitors (TKIs)] (<i>n</i> = 13), failure to (TKIs) treatment (<i>n</i> = 13) and healthy controls (<i>n</i> = 6) were collected. DNA was extracted and treated with bisulfite treatment, followed by PCR, sequencing of 25 CpG sites in the promoter region and 26 CpG sites in intron-1 region of <i>PTPRG</i>. The bisulfite sequencing technique was employed as a high-resolution method.</p><h3>Results</h3><p dir="ltr">CML groups (new diagnosed and failed treatment) showed significantly higher methylation levels in the promoter and intron-1 regions of <i>PTPRG</i> compared to the healthy group. There were also significant differences in methylation levels of CpG sites in the promoter and intron-1 regions amongst the groups.</p><h3>Conclusion</h3><p dir="ltr">Aberrant methylation of <i>PTPRG</i> is potentially one of the possible mechanisms of <i>PTPRG</i> downregulation detected in CML.</p><h2>Other Information</h2><p dir="ltr">Published in: Molecular Genetics & Genomic Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1002/mgg3.1319" target="_blank">http://dx.doi.org/10.1002/mgg3.1319</a></p><p dir="ltr">Additional institutions affiliated with: Qatar University, Qatar University Health - QU, College of Health Sciences - QU HEALTH, Biomedical Research Center - QU HEALTH, Qatar Medical Genetic Center - Hamad General Hospital.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_8b6e8cff37252bc85265e06e6a9aac0c |
| identifier_str_mv | 10.1002/mgg3.1319 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/22258273 |
| publishDate | 2020 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Aberrant DNA methylation of <i>PTPRG</i> as one possible mechanism of its under‐expression in CML patients in the State of QatarMohamed A. Ismail (418629)Muthanna Samara (11619435)Ali Al Sayab (4166521)Mohamed Alsharshani (14778928)Mohamed A. Yassin (8361183)Govindarajulu Varadharaj (14778931)Marzia Vezzalini (212801)Luisa Tomasello (702932)Maria Monne (4166524)Hisham Morsi (14152881)M. Walid Qoronfleh (14153088)Hatem Zayed (835448)Richard Cook (70389)Claudio Sorio (212799)Helmout Modjtahedi (532099)Nader I. Al‐Dewik (14778934)Biological sciencesGeneticsBiomedical and clinical sciencesOncology and carcinogenesisaberrant DNAcancerCMLepigeneticsmethylationPTPRGQatar<h3>Background</h3><p dir="ltr">Several studies showed that aberrant DNA methylation is involved in leukemia and cancer pathogenesis. Protein tyrosine phosphatase receptor gamma (PTPRG) expression is a natural inhibitory mechanism that is downregulated in chronic myeloid leukemia (CML) disease. The mechanism behind its downregulation has not been fully elucidated yet.</p><h3>Aim</h3><p dir="ltr">This study aimed to investigate the CpG methylation status at the <i>PTPRG</i> locus in CML patients.</p><h3>Methods</h3><p dir="ltr">Peripheral blood samples from CML patients at time of diagnosis [no tyrosine kinase inhibitors (TKIs)] (<i>n</i> = 13), failure to (TKIs) treatment (<i>n</i> = 13) and healthy controls (<i>n</i> = 6) were collected. DNA was extracted and treated with bisulfite treatment, followed by PCR, sequencing of 25 CpG sites in the promoter region and 26 CpG sites in intron-1 region of <i>PTPRG</i>. The bisulfite sequencing technique was employed as a high-resolution method.</p><h3>Results</h3><p dir="ltr">CML groups (new diagnosed and failed treatment) showed significantly higher methylation levels in the promoter and intron-1 regions of <i>PTPRG</i> compared to the healthy group. There were also significant differences in methylation levels of CpG sites in the promoter and intron-1 regions amongst the groups.</p><h3>Conclusion</h3><p dir="ltr">Aberrant methylation of <i>PTPRG</i> is potentially one of the possible mechanisms of <i>PTPRG</i> downregulation detected in CML.</p><h2>Other Information</h2><p dir="ltr">Published in: Molecular Genetics & Genomic Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1002/mgg3.1319" target="_blank">http://dx.doi.org/10.1002/mgg3.1319</a></p><p dir="ltr">Additional institutions affiliated with: Qatar University, Qatar University Health - QU, College of Health Sciences - QU HEALTH, Biomedical Research Center - QU HEALTH, Qatar Medical Genetic Center - Hamad General Hospital.</p>2020-07-23T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1002/mgg3.1319https://figshare.com/articles/journal_contribution/Aberrant_DNA_methylation_of__i_PTPRG_i__as_one_possible_mechanism_of_its_under_expression_in_CML_patients_in_the_State_of_Qatar/22258273CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/222582732020-07-23T06:00:00Z |
| spellingShingle | Aberrant DNA methylation of <i>PTPRG</i> as one possible mechanism of its under‐expression in CML patients in the State of Qatar Mohamed A. Ismail (418629) Biological sciences Genetics Biomedical and clinical sciences Oncology and carcinogenesis aberrant DNA cancer CML epigenetics methylation PTPRG Qatar |
| status_str | publishedVersion |
| title | Aberrant DNA methylation of <i>PTPRG</i> as one possible mechanism of its under‐expression in CML patients in the State of Qatar |
| title_full | Aberrant DNA methylation of <i>PTPRG</i> as one possible mechanism of its under‐expression in CML patients in the State of Qatar |
| title_fullStr | Aberrant DNA methylation of <i>PTPRG</i> as one possible mechanism of its under‐expression in CML patients in the State of Qatar |
| title_full_unstemmed | Aberrant DNA methylation of <i>PTPRG</i> as one possible mechanism of its under‐expression in CML patients in the State of Qatar |
| title_short | Aberrant DNA methylation of <i>PTPRG</i> as one possible mechanism of its under‐expression in CML patients in the State of Qatar |
| title_sort | Aberrant DNA methylation of <i>PTPRG</i> as one possible mechanism of its under‐expression in CML patients in the State of Qatar |
| topic | Biological sciences Genetics Biomedical and clinical sciences Oncology and carcinogenesis aberrant DNA cancer CML epigenetics methylation PTPRG Qatar |